TABLE 2.
Comparison of CMV DNA loads in patient serum and plasma specimensa
| Subject | No. of copies of CMV DNA/ml
|
|||
|---|---|---|---|---|
| Plasma with heparin | Plasma with citrate | Plasma with EDTA | Serum | |
| A (RTX) | NAb | 446 | 497 | 31 |
| NA | 463 | 549 | 20 | |
| B (RTX) | 57 | 160 | 159 | Negc |
| 59 | 146 | 137 | Neg | |
| C (RTX) | NA | 351 | 689 | Neg |
| NA | 802 | 668 | 58 | |
| D (ABMT) | ||||
| Day 49 | NA | NA | 287 | 166 |
| Day 52 | NA | NA | 631 | 387 |
| Day 54 | NA | NA | 3,872 | 1,121 |
| E (AIDS) | 5,518 | 2,313 | 10,649 | 809 |
| 7,095 | 6,774 | 9,644 | 580 | |
| F (RTX) | NA | NA | 300 | Neg |
| G (RTX) | ||||
| Day 32 | NA | NA | 1,715 | 75 |
| Day 41 | NA | NA | 1,636 | 83 |
a
Q-PCR CMV loads in paired serum and plasma specimens from five renal transplant patients (RTX), one AIDS patient, and one allogeneic bone marrow transplantation (ABMT) patient; days after transplantation are given where applicable. Data for subjects A, B, C, and E were obtained from duplicate Q-PCR assays.
b
NA, not available.
c
Neg, negative.